ESMO Presentation, page-4

2011 study conclusion - "The combination of IV phenoxodiol with cisplatin or paclitaxel was well tolerated in this study. Cisplatin-phenoxodiol was particularly active and warrants further study in patients with platinum-resistant ovarian cancer".

2018 study conclusion - "NOX66 at 800mg is well tolerated as monotherapy and in combination with low dose carboplatin. Efficacy signals support further investigation of NOX66 in combination with standard chemotherapy."

Almost word for word. And the mathematical numbers in terms of percentage are almost the same as well, except that the 2011 had better efficacy with one complete response, but two low grade toxic response as well. If i was dying I would want to try the drug that at least gave a chance of a complete response.